Companies / BOC Sciences / Pasotuxizumab
BOC Sciences

Pasotuxizumab | BOC Sciences

Pasotuxizumab is a PSMA bispecific T-cell engager (BiTE?) immune therapy mediating T-cell killing of tumor cells in patients with advanced castration-resistant prostate cancer.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.